更新于：2024-11-01

Mike O'Callaghan Federal Medical Center

私营公司

更新于：2024-11-01

概览

关联

项与 Mike O'Callaghan Federal Medical Center 相关的临床试验

NCT06388590 / RecruitingN/AIIT

Acupuncture for Chronic Pelvic Pain

The objective of this study is to determine if alternative pain management strategies, namely acupuncture, may help reduce intensity of female pelvic pain compared to other pain control modalities. This research study will focus specifically on the Dragon's protocol of acupuncture which will seek to alleviate chronic non-endometriosis pelvic pain for women both with and without a history of sexual assault.
This study may support evidence for an inexpensive alternative means of treatment for patients with or without traumatic sexual history and chronic pelvic pain.

开始日期2024-10-01

申办/合作机构

Mike O'Callaghan Federal Medical Center

NCT05887713 / RecruitingN/AIIT

Novel Mental Health Therapies to Improve Military Readiness

To evaluate the efficacy of CES as a therapy to treat and mitigate symptoms of generalized anxiety in DoD beneficiaries in a prospective clinical trial and compare this to sham (placebo) CES.

开始日期2024-01-01

申办/合作机构

Mike O'Callaghan Federal Medical Center

NCT05516862 / RecruitingN/AIIT

Determining the Right Acupuncture for Good Recovery Over Neuropsychiatric Trauma (DRAGON)

This study seeks to verify that a specific acupuncture treatment is effective at reducing symptoms of neuropsychiatric trauma found in those diagnosed with Post-Traumatic Stress Disorder (PTSD).

开始日期2022-10-01

申办/合作机构

Mike O'Callaghan Federal Medical Center

100 项与 Mike O'Callaghan Federal Medical Center 相关的临床结果

登录后查看更多信息

0 项与 Mike O'Callaghan Federal Medical Center 相关的专利（医药）

登录后查看更多信息

项与 Mike O'Callaghan Federal Medical Center 相关的文献（医药）

2020-08-01·Emergency Medicine Journal3区 · 医学

I-FiBH trial: intravenous fluids in benign headaches—a randomised, single-blinded clinical trial

3区 · 医学

Article

作者: Tran, Khanhha ; Martin Manuel, Chris ; Sun, Gina ; Sigal, Tiffany ; Zitek, Tony

BackgroundMany emergency physicians use an intravenous fluid bolus as part of a ‘cocktail’ of therapies for patients with headache, but it is unclear if this is beneficial. The objective of this study was to determine if an intravenous fluid bolus helps reduce pain or improve other outcomes in patients who present to the ED with a benign headache.MethodsThis was a randomised, single-blinded, clinical trial performed on patients aged 10–65 years old with benign headaches who presented to a single ED in Las Vegas, Nevada, from May 2017 to February 2019. All patients received prochlorperazine and diphenhydramine, and they were randomised to also receive either 20 mL/kg up to 1000 mL of normal saline (the fluid bolus group) or 5 mL of normal saline (the control group). The primary outcome was the difference between groups in mean pain reduction 60 min after the initiation of treatment. Secondarily, we compared groups with regards to pain reduction at 30 min, nausea scores, the use of rescue medications and disposition.ResultsWe screened 67 patients for enrolment, and 58 consented. Of those, 35 were randomised to the fluid bolus group and 23 to the control group. The mean pain score dropped by 48.3 mm over 60 min in the fluid bolus group, compared with 48.7 mm in the control group. The between groups difference of 0.4 mm (95% CI −16.5 to 17.3) was not statistically significant (p=0.96). Additionally, no statistically significant difference was found between groups for any secondary outcome.ConclusionThough our study lacked statistical power to detect small but clinically significant differences, ED patients who received an intravenous fluid bolus for their headache had similar improvements in pain and other outcomes compared with those who did not.Trial registration numberNCT03185130.

2020-06-08·Military Medicine4区 · 医学

Understanding Barriers to HPV Vaccination: Perspectives From Air Force Family Medicine Physicians and Active Duty Air Force Males

4区 · 医学

Article

作者: Bepko, Jennifer ; Kline, Randolph J ; Halista, Courtney E

AbstractIntroductionGenital human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. The Center for Disease Control Advisory Committee on Immunization Practices (ACIP) has recognized the potential benefits of immunizing young men beginning at age 11 or 12 years and continuing through age 21 years. The maximum age of immunization is extended through age 26 for men who have sex with men, transgender individuals, and immunocompromised men. In spite of these recommendations, vaccination of young men is currently limited by numerous patient and provider variables. The authors sought to delineate these variables as they pertain to members of the U.S. Air Force in order to guide future interventions.MethodsThe study consisted of two cross-sectional surveys at a single Air Force Base in California. The protocol was approved by the Institutional Review Board at David Grant Medical Center. The physician survey consisted of 10 questions that were formatted and designed to assess physicians’ knowledge about the quadrivalent HPV vaccine (Gardasil) and 6 questions that were formatted and designed to assess physicians’ counseling practices regarding Gardasil. The physician survey was distributed electronically via email in January 2017 to all 48 Family Medicine physicians, including both residents and staff, within the Family Medicine Residency Clinic at Travis Air Force Base. The email contained a link via Microsoft Share-point to an anonymous online survey. The patient survey was distributed in paper form to all male service members between the ages of 18 and 30 years who attended Commander’s Calls over a 90-day period between January 2017 and March 2017. The patient survey included the primary outcome: proportion of respondents who had completed the HPV vaccination series. Descriptive statistics, including frequencies and percentages, were used to summarize the data. Contingency tables were constructed and the chi-square test or Fisher’s Exact Test were performed to determine if particular demographic variables were associated with correct answers to individual knowledge questions.ResultsThe majority of the Family Medicine physicians surveyed have adequate knowledge of HPV and the vaccine but do not routinely offer the vaccine to their male patients. Inadequate time during the office visit was cited as the major limitation to vaccine promotion. Of the Active Duty Air Force males surveyed, only 27% completed the vaccine series. A lack of knowledge regarding the personal benefits of the vaccine and failure to remember to receive subsequent doses were cited as barriers to completion. Only one-quarter of all surveyed males were interested in speaking with a healthcare provider about HPV and/or the HPV vaccine.ConclusionDeficiencies in public knowledge and insufficient provider practices are likely contributing to the suboptimal rates of HPV vaccination among eligible males. Additionally, eligible males are not interested in speaking with their healthcare providers about either HPV or the HPV vaccine. If the rates of HPV vaccination within the male population are to increase, health educators, public health proponents, and vaccine advocates need to devise a more effective approach to disseminate this information to eligible male recipients.

2020-01-01·Management of Hereditary Colorectal Cancer

Early-Age-of-Onset Colorectal Carcinoma: An Emerging Public Health Issue

作者: Jose G. Guillem ; Garrett Friedman ; Aung K. Win

The etiology of colorectal cancer (CRC) is complex and appears to involve a combination of underlying genetic susceptibility, somatic alterations, and environmental exposures which people experience since conception. Young age at diagnosis is a hallmark of hereditary cancer syndromes as discussed in the chapters that follow. Currently known genetic predispositions to CRC include Lynch syndrome (caused by germline mutations in DNA mismatch repair genes), familial adenomatous polyposis (due to APC mutations), MUTYH-associated polyposis (due to mutations in both alleles of MUTYH gene), and germline mutations in other genes such as SMAD4, BRCA1, TP53, POLE, and POLD1. However, only 20–30% of CRC diagnosed under age 50 are attributable to these known hereditary syndromes. The remaining majority of young adult CRC may be associated with other genetic predispositions which have yet to be identified, polygenic factors such as single-nucleotide polymorphisms (SNPs), and/or environmental and lifestyle factors of the person. An analysis of 450 patients diagnosed with CRC under the age of 50 detected 75 gene mutations in 72 patients for a mutation rate of 16%. Of note, 33% of the patients that had a gene mutation did not meet current guidelines for genetic testing. The high frequency and wide spectrum of mutations noted in this study support the argument for more routine multigene testing. In addition, these results are consistent with older studies demonstrating that the frequency of HNPCC (previous name for clinical diagnosis of Lynch syndrome) in CRC patients 40–45 years of age ranges between 15 and 20%, which is greater than a fourfold increase in the rate of HNPCC noted in non-age-stratified CRC.

100 项与 Mike O'Callaghan Federal Medical Center 相关的药物交易

登录后查看更多信息

100 项与 Mike O'Callaghan Federal Medical Center 相关的转化医学

登录后查看更多信息